BBIO vs. RGEN: BridgeBio Pharma vs. Repligen Stock Comparison
How do BridgeBio Pharma (BBIO) and Repligen (RGEN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
BridgeBio Pharma (BBIO) and Repligen (RGEN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BBIO is classified in Biotechnology while RGEN is classified in Life Sciences Tools & Services.
| Profile Item | BBIO | RGEN |
|---|---|---|
| Name | BridgeBio Pharma Inc. | Repligen Corporation |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Life Sciences Tools & Services |
| GICS Sub-Industry | Biotechnology | Life Sciences Tools & Services |
| Market Capitalization | 14.47 billion USD | 11.09 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | June 27, 2019 | April 29, 1986 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | BBIO | RGEN |
|---|---|---|
| Total Return (1Y) | 22.70% | 23.28% |
| Total Return (3Y, Annualized) | 40.97% | 6.20% |
| Total Return (5Y, Annualized) | 8.25% | -8.41% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | BBIO | RGEN |
|---|---|---|
| Volatility (1Y, Annualized) | 44.39% | 46.73% |
| Beta (5Y) | 0.93 | 1.11 |
| Max Drawdown (5Y) | -89.79% | -64.67% |
| Avg. Volume (3M) | 2.68M | 1.18M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | BBIO | RGEN |
|---|---|---|
| Sharpe Ratio (1Y) | 0.41 | 0.41 |
| Sortino Ratio (1Y) | 0.63 | 0.60 |
Profitability
ROE (TTM)
BridgeBio Pharma (BBIO) has no ROE value reported for this period; Repligen (RGEN) reports a negative figure of -0.57%, which needs context because negative ROE can reflect losses or negative shareholders’ equity.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
- BBIO
- --
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-0.57%
- Max
- 109.18%
- Q3
- 6.23%
- RGEN
- -0.57%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Both BridgeBio Pharma (BBIO) at -59.84% and Repligen (RGEN) at -1.47% report negative net margin values, usually indicating net losses over the period.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
-59.84%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
- BBIO
- -59.84%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-1.47%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- RGEN
- -1.47%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
BridgeBio Pharma (BBIO) reports a negative operating margin of -3.30%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Repligen (RGEN) reports 6.19%, ranking against industry peers normally.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
-3.30%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- BBIO
- -3.30%
- Q1
- -78.82%
- Min
- -207.40%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.19%
- Max
- 83.12%
- Q3
- 14.77%
- RGEN
- 6.19%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | BBIO | RGEN |
|---|---|---|
| ROE (TTM) | -- | -0.57% |
| ROA (TTM) | -13.97% | 1.40% |
| Net Margin (TTM) | -59.84% | -1.47% |
| Operating Margin (TTM) | -3.30% | 6.19% |
| Gross Margin (TTM) | 94.34% | 53.77% |
Growth
Revenue Growth
BridgeBio Pharma (BBIO) at 126.26% sits in the top revenue growth quartile, while Repligen (RGEN) at 16.36% is closer to the peer norm — faster top-line expansion for BBIO.
EPS Growth
Neither BridgeBio Pharma (BBIO) nor Repligen (RGEN) reports a EPS growth value for this period, so a direct comparison isn't possible.
Growth Metrics
| Metric | BBIO | RGEN |
|---|---|---|
| Revenue Growth (YoY) | 126.26% | 16.36% |
| Revenue Growth (3Y CAGR) | 86.30% | -2.70% |
| EPS Growth (YoY) | -- | -- |
| EPS Growth (3Y CAGR) | -- | -35.73% |
Financial Strength
Current Ratio (MRQ)
Repligen (RGEN) at 9.88 keeps current ratio within its industry’s typical mid-range, while BridgeBio Pharma (BBIO) at 2.09 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for BBIO.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.09
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- BBIO
- 2.09
- Min
- 0.10
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.88
- Max
- 25.13
- Q3
- 12.13
- RGEN
- 9.88
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Only one side’s leverage can be read here: Repligen (RGEN) carries debt-to-equity ratio of 0.33 against its industry range, while BridgeBio Pharma (BBIO) reports no figure this period.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
- BBIO
- --
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.33
- Max
- 1.42
- Q3
- 0.65
- RGEN
- 0.33
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | BBIO | RGEN |
|---|---|---|
| Current Ratio (MRQ) | 2.09 | 9.88 |
| Debt / Equity (MRQ) | -- | 0.33 |
| Net Debt / EBITDA | -- | -1.19 |
Dividends
Dividend Yield (TTM)
Neither BridgeBio Pharma (BBIO) nor Repligen (RGEN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BBIO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- RGEN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither BridgeBio Pharma (BBIO) nor Repligen (RGEN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BBIO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- RGEN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | BBIO | RGEN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Neither BridgeBio Pharma (BBIO) nor Repligen (RGEN) reports a P/E ratio value for this period, so a direct comparison isn’t possible.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- BBIO
- --
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- RGEN
- --
P/S Ratio (TTM)
On P/S ratio, both BridgeBio Pharma (BBIO) at 15.31 and Repligen (RGEN) at 13.77 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
15.31
- Max
- 58.18
- Q3
- 25.77
- BBIO
- 15.31
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.77
- Max
- 58.18
- Q3
- 25.77
- RGEN
- 13.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
BridgeBio Pharma (BBIO) reports a negative P/B ratio of -5.59, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Repligen (RGEN) reports 4.70, ranking against industry peers normally.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
-5.59
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- BBIO
- -5.59
- Min
- -5.59
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.70
- Max
- 13.53
- Q3
- 6.54
- RGEN
- 4.70
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | BBIO | RGEN |
|---|---|---|
| P/E Ratio (TTM) | -- | -- |
| P/S Ratio (TTM) | 15.31 | 13.77 |
| P/B Ratio (MRQ) | -5.59 | 4.70 |
| Free Cash Flow Yield (TTM) | -1.98% | 1.01% |